Tower Research Capital LLC (Trc) I Mab Transaction History

Tower Research Capital LLC (Trc)

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$1.21 - $1.9 $4,247 - $6,669	-3,510 Reduced 12.48%	24,608 $46,000
Q3 2023 Nov 14, 2023	BUY	$1.18 - $3.06 $24,158 - $62,647	20,473 Added 267.8%	28,118 $37,000
Q2 2023 Aug 14, 2023	BUY	$2.95 - $3.85 $8,723 - $11,384	2,957 Added 63.08%	7,645 $22,000
Q1 2023 May 09, 2023	SELL	$3.08 - $7.39 $5,639 - $13,531	-1,831 Reduced 28.09%	4,688 $16,000
Q4 2022 Feb 10, 2023	SELL	$3.22 - $4.86 $201,733 - $304,479	-62,650 Reduced 90.58%	6,519 $27,000

Q3 2022 Nov 10, 2022	BUY	$4.01 - $12.34 $270,225 - $831,567	67,388 Added 3783.72%	69,169 $278,000
Q2 2022 Aug 15, 2022	SELL	$8.27 - $18.43 $28,175 - $62,791	-3,407 Reduced 65.67%	1,781 $20,000
Q1 2022 May 12, 2022	BUY	$12.54 - $46.93 $53,006 - $198,373	4,227 Added 439.85%	5,188 $84,000
Q4 2021 Feb 14, 2022	SELL	$45.28 - $74.5 $64,116 - $105,492	-1,416 Reduced 59.57%	961 $46,000
Q3 2021 Nov 15, 2021	BUY	$57.18 - $84.43 $88,686 - $130,950	1,551 Added 187.77%	2,377 $172,000
Q2 2021 Aug 16, 2021	BUY	$47.86 - $83.95 $6,030 - $10,577	126 Added 18.0%	826 $69,000
Q1 2021 May 17, 2021	BUY	$44.38 - $63.97 $21,524 - $31,025	485 Added 225.58%	700 $34,000
Q4 2020 Feb 16, 2021	BUY	$32.94 - $47.15 $7,082 - $10,137	215 New	215 $10,000

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $125M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.